J & J Settlement Pays Off For Nation’s Capital
- November 18, 2013 by Qui Tam
- Federal False Claims Act, Healthcare, Pharmaceuticals
The government’s recent massive settlement with Johnson & Johnson is paying dividends for the residents of Washington, D.C.
The District of Columbia’s Medicaid program will receive more than $3 million out of the $1.2 billion settlement, which resolved four qui tam cases filed in federal court in the Eastern District of Pennsylvania.
The suits contended that Johnson & Johnson and subsidiary Janssen Pharmaceuticals, Inc., engaged in off-label promotion of antipsychotic drugs Risperdal and Invega.